Drug reference

Ertugliflozin

SGLT2 Inhibitor · Antidiabetic

SGLT2 InhibitorAntidiabetic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactions

GatifloxacinSevereDatabaseDDInter

Mechanism

Ertugliflozin reversibly inhibits sodium-glucose cotransporter 2 (SGLT2) in the renal proximal convoluted tubule. This action reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose levels in patients with type 2 diabetes.

Indications

Type 2 diabetes mellitus as monotherapy (if metformin inappropriate)Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)management of diabetes mellitus (type 2)treatment of type 2 diabetes (combined with metformin as preferred regimen)heart failure with reduced ejection fraction (reduce cardiovascular death and hospitalization)type 2 diabetes (reduce cardiovascular mortality, nonfatal stroke, nonfatal myocardial infarction, hospitalization for heart failure, total mortality)protect against declining renal function in type 2 diabetesprotect against end-stage kidney disease in type 2 diabetesprotect against death due to kidney disease in type 2 diabetesprotect against acute kidney injury in type 2 diabetesTreatment of type 2 diabetes (in combination with other oral agents and insulin)

Dosing

Adult: BY MOUTH: 5 mg once daily; increased to 15 mg once daily if necessary and if tolerated, dose to be taken in the morning
Max dose: 15 mg once daily

Pharmacokinetics

Peak effect

1-2 h

Half-life

11–17

Bioavailability

Rapidly absorbed from GI tract

Protein binding

highly protein bound (>85%)

Metabolism

hepatic metabolism

Excretion

excretion of metabolites in the urine and feces

Contraindications

severe renal impairment
end-stage renal disease

Side effects

Common

reproductive tract infectionsurinary tract infectionshypoglycemiapolyuriadehydrationhyperphosphatemiahypermagnesemiahyperkalemiahypovolemiahypotensionLower urinary tract infectionsGenital mycotic infectionsTransient worsening of renal function

Serious

Diabetic ketoacidosis (DKA), which can be serious, life-threatening, and fatal, sometimes with atypical presentation (moderately elevated blood glucose levels)
ketoacidosis (rare)
reduced bone density
bone fractures
lower limb amputation (controversial)
tumorgenicity (controversial)
necrotizing fasciitis of perineum
Diabetic ketoacidosis (euglycemic DKA)